Every material Form 8-K Quoin Pharmaceuticals Ltd. has filed with the SEC since October 14, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Quoin Pharmaceuticals reported a net loss of $4.9 million for the quarter ended September 30, 2026, up from $3.9 million a year earlier, and a nine-month net loss of $15.2 million versus $11.5 million. The company said it had about $33.2 million in cash, cash equivalents and marketable securities at quarter end, and it highlighted positive interim Netherton Syndrome data and new regulatory designations. Shareholders see a wider loss alongside clinical and regulatory progress.
Q3 2026 net loss was approximately $4.9 million, compared with approximately $3.9 million in Q3 2025.
Nine-month 2026 net loss was approximately $15.2 million, compared with approximately $11.5 million for the same period in 2025.
Cash, cash equivalents and marketable securities were approximately $33.2 million as of September 30, 2026.
Up to $50.0 million private placement was announced August 28, 2026, with approximately $30.8 million in initial upfront funding.
Quoin Pharmaceuticals signed a sales agreement with Leerink Partners LLC that lets it sell American Depositary Shares from time to time through an at-the-market offering. Leerink would receive 3.0% of gross sale proceeds, and the filing does not state a dollar amount or number of shares to be sold, so the potential dilution to shareholders is not quantified.
Sales agreement with Leerink Partners LLC dated November 4, 2026; each ADS represents 35 ordinary shares.
Leerink Partners would be paid 3.0% of gross sale proceeds from ADSs sold through it.
Sales are made under Form S-3 (File No. 333-299668), declared effective November 4, 2026; the filing states no aggregate offering size.
Either party may suspend or terminate the agreement at any time upon notice.
Quoin Pharmaceuticals announced the online publication of a peer-reviewed paper introducing its investigational lotion QRX003 and a single pediatric compassionate-use case report. The filing presents single-patient observations only and does not report new trial results, revenue, or financial measures, so the announcement is clinical-awareness news rather than a financial result.
Paper published online October 13, 2026 in Dermatology and Therapy and announced October 20, 2026
Single pediatric patient's IGA score improved from 4 (severe) to 1 (almost clear) after six weeks and reached 0 by eight months
Company expects to complete recruitment of 20 participants in Phase 2/3 study CL-QRX003-004 by end of 2026 and report topline data in Q2 2027
Quoin Pharmaceuticals said on October 14, 2026 that the European Medicines Agency granted Orphan Drug Designation to its lead product candidate QRX003 for treating Peeling Skin Syndrome. If QRX003 is approved for marketing by the EMA, the company would receive 10 years of market exclusivity in Europe for similar medicines for this indication, and the company plans to start the first-ever formal clinical study for the condition before year end.
EMA granted Orphan Drug Designation to QRX003 for Peeling Skin Syndrome, announced October 14, 2026
Designation brings scientific advice on study protocols, various fee reductions and access to EU grants
If approved by the EMA, QRX003 would receive 10 years of market exclusivity in Europe for this indication
The company intends to initiate the first-ever formal clinical study for Peeling Skin Syndrome before year end
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Quoin Pharmaceuticals Ltd. filing is on SEC EDGAR ↗. 8-K briefs of other companies →